I
Imad Nasser
Researcher at Beth Israel Deaconess Medical Center
Publications - 67
Citations - 3699
Imad Nasser is an academic researcher from Beth Israel Deaconess Medical Center. The author has contributed to research in topics: Liver biopsy & Nonalcoholic fatty liver disease. The author has an hindex of 26, co-authored 63 publications receiving 3158 citations. Previous affiliations of Imad Nasser include Brigham and Women's Hospital & Boston University.
Papers
More filters
Journal ArticleDOI
2016 Comprehensive Update of the Banff Working Group on Liver Allograft Pathology: Introduction of Antibody-Mediated Rejection.
Anthony J. Demetris,Christopher Bellamy,Stefan G. Hubscher,Jacqueline G. O'Leary,Parmjeet Randhawa,Sandy Feng,Desley Neil,Robert B. Colvin,Geoffrey W. McCaughan,John J. Fung,A. Del Bello,Finn P. Reinholt,Hironori Haga,Oyedele Adeyi,A J Czaja,Thomas D. Schiano,Maria Isabel Fiel,Maxwell L. Smith,Mylène Sebagh,R Y Tanigawa,Funda Yilmaz,Graeme J.M. Alexander,L Baiocchi,M Balasubramanian,Ibrahim Batal,Atul K. Bhan,John C. Bucuvalas,Carlos Thadeu Schmidt Cerski,F Charlotte,M. E. de Vera,M ElMonayeri,Paulo Fontes,Emma E. Furth,Annette S. H. Gouw,Sara Hafezi-Bakhtiari,John Hart,E Honsova,Wesam Ismail,Tomoo Itoh,N C Jhala,Urmila Khettry,Goran B. Klintmalm,Stuart J. Knechtle,Takaaki Koshiba,Tomasz Kozlowski,Charles Lassman,Jan Lerut,Josh Levitsky,L Licini,R Liotta,George V. Mazariegos,Marta I. Minervini,Joseph Misdraji,Thalachallour Mohanakumar,Johan Mölne,Imad Nasser,James Neuberger,M O'Neil,O Pappo,L Petrovic,Phillip Ruiz,Ozgul Sagol,A Sanchez Fueyo,Eizaburo Sasatomi,Abraham Shaked,M. Shiller,T Shimizu,Banu Sis,Aurelio Sonzogni,Heather L. Stevenson,Swan N. Thung,Giuseppe Tisone,Athanassios C. Tsamandas,Annika Wernerson,Tong Wu,A. Zeevi,Yoh Zen +76 more
TL;DR: New recommendations for complement component 4d tissue staining and interpretation, staging liver allograft fibrosis, and findings related to immunosuppression minimization are included.
Journal ArticleDOI
Hepatitis C genotype 4: What we know and what we don't yet know.
Sanaa M. Kamal,Imad Nasser +1 more
TL;DR: HCV‐4 infection is spreading beyond its strongholds in Africa and the Middle East, and tailored treatment options that are comparable to the treatment approaches for genotype 1, 2, and 3 patients to optimize treatment for each patient are now being developed.
Journal ArticleDOI
The clinical significance of persistently normal ALT in chronic hepatitis B infection.
TL;DR: Subgroup analysis showed the majority with fibrosis belonged to the high normal ALT group and that only a minority who were young and immune tolerant had significant findings on biopsy, and increasing age, higher ALT, higher grade of inflammation on bi autopsy, and HBeAg positivity predicted fibrosis.
Journal ArticleDOI
Occult axillary lymph node metastases in “node-negative” breast carcinoma
Imad Nasser,Arthur K.C. Lee,Arthur K.C. Lee,Silvano Bosari,Silvano Bosari,Rebecca Saganich,Rebecca Saganich,Gerald I. Heatley,Gerald I. Heatley,Mark L. Silverman,Mark L. Silverman +10 more
TL;DR: The data suggest that occult metastases < or = 0.2 mm, especially those consisting of single cells, do not add useful prognostic information, and immunohistochemical studies to detect them are probably unnecessary.
Journal ArticleDOI
Fibroblast growth factor 21 limits lipotoxicity by promoting hepatic fatty acid activation in mice on methionine and choline-deficient diets.
ffolliott M. Fisher,Patricia Chui,Imad Nasser,Yury Popov,Jeremy C. Cunniff,Thomas Lundasen,Alexei Kharitonenkov,Detlef Schuppan,Detlef Schuppan,Jeffrey S. Flier,Eleftheria Maratos-Flier +10 more
TL;DR: FGF21 regulates fatty acid activation and oxidation in livers of mice, and in the absence of FGF21, accumulation of inactivated fatty acids results in lipotoxic damage and increased steatosis.